Breast and cervical cancer screening programme implementation in 16 countries
- PMID: 20956724
- DOI: 10.1258/jms.2010.010033
Breast and cervical cancer screening programme implementation in 16 countries
Abstract
Objectives: There is a continuing need to monitor and evaluate the impact of organized screening programmes on cancer incidence and mortality. We report results from a programme assessment conducted within the International Cancer Screening Network (ICSN) to understand the characteristics of cervical screening programmes within countries that have established population-based breast cancer screening programmes.
Methods: In 2007-2008, we asked 26 ICSN country representatives to complete a web-based survey that included questions on breast and cervical cancer screening programmes. We summarized information from 16 countries with both types of organized programmes.
Results: In 63% of these countries, the organization of the cervical cancer screening programme was similar to that of the breast cancer screening programme in the same country. There were differences in programme characteristics, including year established (1962-2003 cervical; 1986-2002 breast) and ages covered (15-70+ cervical; 40-75+ breast). Adoption of new screening technologies was evident (44% liquid-based Pap tests; 13% human papillomavirus (HPV)-triage tests cervical; 56% digital mammography breast). There was wide variation in participation rates for both programme types (<4-80% cervical; 12-88% breast), and participation rates tended to be higher for cervical (70-80%) than for breast (60-70%) cancer screening programmes. Eleven ICSN member countries had approved the HPV vaccine and five more were considering its use in their organized programmes.
Conclusion: Overall, there were similarities and differences in the organization of breast and cervical cancer screening programmes among ICSN countries. This assessment can assist established and new screening programmes in understanding the organization and structure of cancer screening programmes.
Similar articles
-
Effect of screening for cancer in the Nordic countries on deaths, cost and quality of life up to the year 2017.Acta Oncol. 1997;36 Suppl 9:1-60. Acta Oncol. 1997. PMID: 9143316
-
[The general criteria and recommendations for the elaboration of programs for the early detection of breast cancer and cervical cancer in Spain. The Working Group for the Early Detection of Breast Cancer and Cervical Cancer].Rev Sanid Hig Publica (Madr). 1993 Jan-Feb;67(1):23-37. Rev Sanid Hig Publica (Madr). 1993. PMID: 7725048 Spanish.
-
Cancer screening in Singapore, with particular reference to breast, cervical and colorectal cancer screening.J Med Screen. 2006;13 Suppl 1:S14-9. J Med Screen. 2006. PMID: 17227636
-
Effective screening programmes for cervical cancer in low- and middle-income developing countries.Bull World Health Organ. 2001;79(10):954-62. Epub 2001 Nov 1. Bull World Health Organ. 2001. PMID: 11693978 Free PMC article. Review.
-
[Responsible cancer screening].Ned Tijdschr Geneeskd. 2011;155(45):A3934. Ned Tijdschr Geneeskd. 2011. PMID: 22085573 Review. Dutch.
Cited by
-
Cervical screening at age 50-64 years and the risk of cervical cancer at age 65 years and older: population-based case control study.PLoS Med. 2014 Jan;11(1):e1001585. doi: 10.1371/journal.pmed.1001585. Epub 2014 Jan 14. PLoS Med. 2014. PMID: 24453946 Free PMC article.
-
Real-world efficiency of pharmacogenetic screening for carbamazepine-induced severe cutaneous adverse reactions.PLoS One. 2014 May 7;9(5):e96990. doi: 10.1371/journal.pone.0096990. eCollection 2014. PLoS One. 2014. PMID: 24806465 Free PMC article.
-
Predictors of Breast Cancer Screening behavior in Women aged 20-69 Referred to Public Health Centers: A Cross-Sectional Study in Isfahan Province.Int J Prev Med. 2022 Sep 20;13:115. doi: 10.4103/ijpvm.IJPVM_466_20. eCollection 2022. Int J Prev Med. 2022. PMID: 36276893 Free PMC article.
-
Clinical application of DNA ploidy to cervical cancer screening: A review.World J Clin Oncol. 2014 Dec 10;5(5):931-65. doi: 10.5306/wjco.v5.i5.931. World J Clin Oncol. 2014. PMID: 25493231 Free PMC article. Review.
-
Clinical implications of AGBL2 expression and its inhibitor latexin in breast cancer.World J Surg Oncol. 2014 May 7;12:142. doi: 10.1186/1477-7819-12-142. World J Surg Oncol. 2014. PMID: 24884516 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Research Materials